LB202

LB202 is a preclinical-stage small molecule being developed by Leadiant Biosciences (formerly Sigma-Tau) for the treatment of cystinosis. Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, which encodes the lysosomal cystine transporter cystinosin. This deficiency leads to the accumulation of cystine within lysosomes, resulting in crystal formation and progressive organ damage, most notably in the kidneys (renal Fanconi syndrome) and eyes. LB202 is intended as a next-generation cystine-depleting agent, potentially aiming to improve upon the limitations of current cysteamine-based therapies, such as frequent dosing requirements and significant gastrointestinal side effects. As a new chemical entity, LB202 represents a continued effort by Leadiant Biosciences to address unmet needs in the cystinosis patient population, building on their experience as the developer of the first-generation treatment, Cystagon (cysteamine bitartrate).